Gustavo Adolfo Vásquez-Tirado

Dr. Gustavo Adolfo Vásquez-Tirado

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

24 September 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
GVGustavo Adolfo Vásquez-Tirado
Gustavo Adolfo Vásquez-Tirado
CQClaudia Vanessa Quispe-Castañeda
Claudia Vanessa Quispe-Castañeda
EMEdinson Dante Meregildo-Rodríguez
Edinson Dante Meregildo-Rodríguez
MCMaría Cuadra-Campos
María Cuadra-Campos
NSNiler Manuel Segura-Plasencia
Niler Manuel Segura-Plasencia
PZPetterson Zavaleta-Alaya
Petterson Zavaleta-Alaya
Introduction: Septic shock still entails significant morbidity and mortality, with the heart being affected due to catecholamine overexpression and direct injury from sepsis. Therefore, the effect of β-blocking the receptors to improve performance is promising when attempting to reverse tachycardia and reduce mortality.Methods: We conducted a comprehensive search across five databases for studies published up to 28 January 2024, using a PICO strategy. Ten studies were identified for quantitative analysis and included in our meta-analysis.Results: Our meta-analysis evaluated 28-day in-hospital mortality risk across nine randomized controlled trials (RCTs) involving a total of 1,121 adults with septic shock. We found an association between β-blocker use and reduced overall mortality (OR 0.57; 95% CI 0.34–0.98; I2: 56%). This effect was significant in the esmolol subgroup (OR 0.47; 95% CI 0.26–0.82; I2: 32%), but not in the landiolol subgroup (OR 0.98; 95% CI 0.0–1,284.5; I2: 72%). Additionally, the intervention group shows a significant reduction in HR and lactate levels, as well as an increase in stroke volume index (SVI).Conclusion: In adults with septic shock, β-blockers are associated with a reduction in 28-day in-hospital mortality, a benefit primarily observed with esmolol rather than landiolol. Furthermore, improvements in heart rate (HR) control, lactate levels, and SVI were noted. However, these findings should be interpreted with caution, and further high-quality RCTs comparing different β-blockers are necessary to better elucidate these effects.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024513610.

29 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Edinson Dante Meregildo RodriguezEdinson Dante Meregildo Rodriguez
Edinson Dante Meregildo Rodriguez
MAMartha Genara Asmat-Rubio
Martha Genara Asmat-Rubio
MRMayra Janett Rojas-Benites
Mayra Janett Rojas-Benites
GVGustavo Adolfo Vásquez-Tirado
Gustavo Adolfo Vásquez-Tirado
One-third of adult inpatients with community-acquired pneumonia (CAP) develop acute coronary syndrome (ACS), stroke, heart failure (HF), arrhythmias, or die. The evidence linking CAP to cardiovascular disease (CVD) events is contradictory. We aimed to systematically review the role of CAP as a CVD risk factor. We registered the protocol (CRD42022352910) and searched for six databases from inception to 31 December 2022. We included 13 observational studies, 276,109 participants, 18,298 first ACS events, 12,421 first stroke events, 119 arrhythmic events, 75 episodes of new onset or worsening HF, 3379 deaths, and 218 incident CVD events. CAP increased the odds of ACS (OR 3.02; 95% CI 1.88–4.86), stroke (OR 2.88; 95% CI 2.09–3.96), mortality (OR 3.22; 95% CI 2.42–4.27), and all CVD events (OR 3.37; 95% CI 2.51–4.53). Heterogeneity was significant (I2 = 97%, p < 0.001). Subgroup analysis found differences according to the continent of origin of the study, the follow-up length, and the sample size (I2 > 40.0%, p < 0.10). CAP is a significant risk factor for all major CVD events including ACS, stroke, and mortality. However, these findings should be taken with caution due to the substantial heterogeneity and the possible publication bias.

Verified
Journal Article
Open access
PDF file
Edinson Dante Meregildo RodriguezEdinson Dante Meregildo Rodriguez
Edinson Dante Meregildo Rodriguez
Edinson Dante Meregildo RodriguezEdinson Dante Meregildo Rodriguez
Edinson Dante Meregildo Rodriguez
PZPetterson Zavaleta-Alaya
Petterson Zavaleta-Alaya
GVGustavo Adolfo Vásquez-Tirado
Gustavo Adolfo Vásquez-Tirado
Tuberculosis and diabetes mellitus are two global pandemics and rising public health problems. Recent studies suggest that oral antidiabetic drugs (OADs) could reduce the risk of tuberculosis and improve clinical outcomes. However, the evidence is controversial. Therefore, we aimed to assess the effect of OADs on the risk of tuberculosis and treatment outcomes. We systematically searched for six databases from inception to 31 August 2022. We followed a predefined PICO/PECO strategy and included two randomized controlled trials and sixteen observational studies. This study collects 1,109,660 participants, 908,211 diabetic patients, and at least 13,841 tuberculosis cases. Our results show that metformin decreases the risk of active tuberculosis by 40% (RR 0.60; 95% CI 0.47–0.77) in diabetic patients. In addition, metformin exhibits a dose-response gradient (medium doses reduce the risk of active tuberculosis by 45%, while high doses reduce this risk by 52%). On the other hand, DPP IV inhibitors increase the risk of active tuberculosis by 43% (RR 1.43; 95% CI 1.02–2.02). Subgroup analysis showed that study design and metformin dose accounted for the heterogeneity. We conclude that metformin significantly protects against active tuberculosis among diabetic patients. On the contrary, DPP IV inhibitors could increase the risk of developing active tuberculosis.

24 January 2025 in European Journal of Trauma and Emergency Surgery
Verified
Journal Article
Closed access
PDF file
DMDiego Moncada-Gutiérrez
Diego Moncada-Gutiérrez
GVGustavo Adolfo Vásquez-Tirado
Gustavo Adolfo Vásquez-Tirado
EMEdinson Dante Meregildo-Rodríguez
Edinson Dante Meregildo-Rodríguez
CQClaudia Vanessa Quispe-Castañeda
Claudia Vanessa Quispe-Castañeda
MCMaría Cuadra-Campos
María Cuadra-Campos
LRLuis Ángel Rodríguez-Chávez
Luis Ángel Rodríguez-Chávez

1 March 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
EMEdinson Dante Meregildo-Rodríguez
Edinson Dante Meregildo-Rodríguez
GVGustavo Adolfo Vásquez-Tirado
Gustavo Adolfo Vásquez-Tirado
CQClaudia Vanessa Quispe-Castañeda
Claudia Vanessa Quispe-Castañeda
MCMaría del Carmen Cuadra-Campos
María del Carmen Cuadra-Campos
JCJhuliana M. Contreras-Cabrera
Jhuliana M. Contreras-Cabrera
JPJuan Luis Pinedo-Portilla
Juan Luis Pinedo-Portilla
Introduction: Cervical spinal cord injury (CSCI) patients on mechanical ventilation often lack standardized guidelines for optimal ventilatory support. This study reviews existing literature to compare outcomes between high tidal volume (HTV) and low tidal volume (LTV) strategies in this unique patient population.Methods: We searched for studies published up to August 30, 2023, in five databases, following a PECO/PICO strategy. We found six studies for quantitative analysis and meta-analyzed five studies.Results: This meta-analysis included 396 patients with CSCI and mechanical ventilation (MV), 119 patients treated with high tidal volume (HTV), and 277 with low tidal volume (LTV). This first meta-analysis incorporates the few studies that show contradictory findings. Our meta-analysis shows that there is no significant statistical difference in developing VAP between both comparison groups (HTV vs. LTV) (OR 0.46; 95% CI 0.13 to 1.66; p > 0.05; I2: 0%), nor are there differences between the presence of other pulmonary complications when treating with HTV such as acute respiratory distress syndrome (ARDS), atelectasis, onset of weaning.Conclusion: In patients with CSCI in MV, the use of HTV does not carry a greater risk of pneumonia compared to LTV; in turn, it is shown as a safe ventilatory strategy as it does not establish an increase in other pulmonary complications such as ARDS, atelectasis, the onset of weaning nor others associated with volutrauma. It is necessary to evaluate the role of HTV ventilation in this group of patients in primary RCT-type studies.